Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis

Key facts

Sponsor

Children's Hospital Medical Center, Cincinnati

Principal Investigator

Bruce Trapnell, MD, MD

Children's Hospital Medical Center, Cincinnati

Intervention

Pioglitazone(drug)

Enrollment

3 enrolled

Eligibility

18-80 years · All sexes

Timeline

2017 – 2019

Study locations (1)

• Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Autoimmune pulmonary alveolar proteinosis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06431776
  Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
  Savara Inc.
• RECRUITINGPHASE4NCT07200544
  Meloxicam in Mohs Micrographic Surgery
  University of Oklahoma
• RECRUITINGPHASE4NCT07102641
  Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
  Thomas Jefferson University
• ACTIVE NOT RECRUITINGPHASE2NCT06111846
  Study of Human Bone Marrow Mesenchymal Stem Cells in APAP
  Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
• RECRUITINGPHASE4NCT05425355
  Intravenous vs Oral Acetaminophen in Postoperative Hip Fracture Adult Patients
  University Health Network, Toronto
• ACTIVE NOT RECRUITINGPHASE3NCT04544293
  Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
  Savara Inc.
• RECRUITINGPHASE4NCT03759028
  Supracondylar Post-Operative Pain Study
  University of California, Los Angeles

See all trials for Autoimmune pulmonary alveolar proteinosis →